-
Mashup Score: 0Lipoprotein(a) and subclinical vascular disease progression in children with familial hypercholesterolaemia - 9 month(s) ago
Lipoprotein(a) is a cholesterol-rich particle, high concentrations of which are associated with a greater risk of atherosclerosis and occurrence of aortic valve calcification in the general population.1 This might also be the case for adults affected by familial hypercholesterolaemia,2 a disease in which autosomal dominant genetic defects cause elevated LDL-cholesterol.3–5
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 132023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance - 12 month(s) ago
Abstract. This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides prag
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. #EHJ https://t.co/zcQqb63goG #HoFH #hypercholesterolaemia #diagnosis #treatment #cardiotwitter @escardio @ESC_Journals https://t.co/QDSHRldpiD
-
-
Mashup Score: 7
After 80 weeks of treatment, evolocumab was safe, well tolerated, and led to sustained reductions in LDL cholesterol in paediatric patients with heterozygous familial hypercholesterolaemia. When lipid goals cannot be achieved with conventional treatments, evolocumab is an effective add-on therapy in paediatric patients.
Categories: Endocrinology, Latest HeadlinesTweet-
#Paediatric patients with #heterozygous #familial #hypercholesterolaemia treated with #evolocumab for 80 weeks (#HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT https://t.co/o7iaKX24zS #PCSK9 inhibitor
-
-
Mashup Score: 4PCSK9 inhibition in children with familial hypercholesterolaemia - 1 year(s) ago
Heterozygous familial hypercholesterolaemia is the most prevalent monogenic dyslipidaemia, affecting approximately 1 in 300 people worldwide.1 If left untreated, elevated LDL cholesterol concentrations in heterozygous familial hypercholesterolaemia are associated with a more than ten-fold increased risk of premature atherosclerotic cardiovascular disease.1 For children and adolescents with…
Categories: Endocrinology, Latest HeadlinesTweet-
Robert A Hegele comments on: #PCSK9 inhibition in #children with #familial #hypercholesterolaemia https://t.co/5xmPOVTYYy #evolocumab
-
-
Mashup Score: 2
After 80 weeks of treatment, evolocumab was safe, well tolerated, and led to sustained reductions in LDL cholesterol in paediatric patients with heterozygous familial hypercholesterolaemia. When lipid goals cannot be achieved with conventional treatments, evolocumab is an effective add-on therapy in paediatric patients.
Categories: Endocrinology, Latest HeadlinesTweet-
Paediatric patients with heterozygous familial #hypercholesterolaemia treated with #evolocumab for 80 weeks (#HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT https://t.co/o7iaKX1wKk #PCSK9 inhibitor
-
-
Mashup Score: 1PCSK9 inhibition in children with familial hypercholesterolaemia - 2 year(s) ago
Heterozygous familial hypercholesterolaemia is the most prevalent monogenic dyslipidaemia, affecting approximately 1 in 300 people worldwide.1 If left untreated, elevated LDL cholesterol concentrations in heterozygous familial hypercholesterolaemia are associated with a more than ten-fold increased risk of premature atherosclerotic cardiovascular disease.1 For children and adolescents with…
Categories: Endocrinology, Latest HeadlinesTweet-
Also read the Linked Comment by Robert A Hegele: #PCSK9 inhibition in #children with familial #hypercholesterolaemia https://t.co/5xmPOVTYYy #evolocumab https://t.co/nQxRy5HG2i
-
-
Mashup Score: 6
After 80 weeks of treatment, evolocumab was safe, well tolerated, and led to sustained reductions in LDL cholesterol in paediatric patients with heterozygous familial hypercholesterolaemia. When lipid goals cannot be achieved with conventional treatments, evolocumab is an effective add-on therapy in paediatric patients.
Categories: Endocrinology, Latest HeadlinesTweet-
#Paediatric patients with heterozygous familial #hypercholesterolaemia treated with #evolocumab for 80 weeks (#HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT https://t.co/o7iaKX1wKk #PCSK9 inhibitor
-
-
Mashup Score: 1PCSK9 inhibition in children with familial hypercholesterolaemia - 2 year(s) ago
Heterozygous familial hypercholesterolaemia is the most prevalent monogenic dyslipidaemia, affecting approximately 1 in 300 people worldwide.1 If left untreated, elevated LDL cholesterol concentrations in heterozygous familial hypercholesterolaemia are associated with a more than ten-fold increased risk of premature atherosclerotic cardiovascular disease.1 For children and adolescents with…
Categories: Endocrinology, Latest HeadlinesTweet-
Robert A Hegele comments on: #PCSK9 inhibition in #children with familial #hypercholesterolaemia https://t.co/5xmPOVCnzY #evolocumab https://t.co/6WLKmrBN8w
-
-
Mashup Score: 0
After 80 weeks of treatment, evolocumab was safe, well tolerated, and led to sustained reductions in LDL cholesterol in paediatric patients with heterozygous familial hypercholesterolaemia. When lipid goals cannot be achieved with conventional treatments, evolocumab is an effective add-on therapy in paediatric patients.
Categories: Endocrinology, Latest HeadlinesTweet-
#Paediatric patients with heterozygous familial #hypercholesterolaemia treated with #evolocumab for 80 weeks (#HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT https://t.co/o7iaKX24zS #PCSK9 inhibitor https://t.co/FBYsTEzKhE
-
-
Mashup Score: 0PCSK9 inhibition in children with familial hypercholesterolaemia - 2 year(s) ago
Heterozygous familial hypercholesterolaemia is the most prevalent monogenic dyslipidaemia, affecting approximately 1 in 300 people worldwide.1 If left untreated, elevated LDL cholesterol concentrations in heterozygous familial hypercholesterolaemia are associated with a more than ten-fold increased risk of premature atherosclerotic cardiovascular disease.1 For children and adolescents with…
Categories: Endocrinology, Latest HeadlinesTweet-
Robert A Hegele comments on: #PCSK9 inhibition in #children with familial #hypercholesterolaemia https://t.co/5xmPOVUwO6 #evolocumab https://t.co/ER9pPr6Tt6
-
Raul D Santos comments on: #Lipoprotein(a) and subclinical #vascular disease progression in children with familial #hypercholesterolaemia https://t.co/swSXefq4JA #CVD